Table : Medication characteristics and Levodopa equivalence daily doses (LEDD, Tomlinson et al., 2010; Shade, Mollenhauer & Trenkwalder, 2020) of ON and OFF participants.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **PD off medication** | |  | **PD on medication** | |
|  | **Daily medication** | **LEDD (mg)** |  | **Daily medication** | **LEDD (mg)** |
| 1 | Levodopa (200mg)\*3 + Pramipexole (1.05mg)\*1 + Rasagiline (1mg)\*1 | 805 | 1 | Levodopa (100mg)\*3 | 300 |
| 2 | Levodopa (250mg)\*3 + Pramipexole ER (0.56mg) | 806 | 2 | Levodopa (200mg)\*3 + Entacapone (200mg)\*3 | 798 |
| 3 | Levodopa (250mg)\*3 + Rasagiline (1mg)\*1 | 850 | 3 | Levodopa (250mg)\*3 + Piribedil ER (50mg)\*3 | 900 |
| 4 | Levodopa (100mg)\*4.5 | 450 | 4 | Levodopa (150mg)\*2 + Levodopa (200mg)\*3 + Entacapone (200mg)\*5 + Pramipexole (2.1mg)\*1 + Pramipexole (1.05mg)\*2 + Rasagiline (1mg)\*1 | 1750 |
| 5 | Levodopa (100mg)\*3 + Levodopa (75mg)\*4 + Entacapone (200mg)\*4 + Piribedil ER (50mg)\*3 | 1014 | 5 | Levodopa (250mg)\*2 | 500 |
| 6 | Levodopa (250mg)\*6 | 1500 | 6 | Levodopa (150mg)\*2 + Levodopa (200mg)\*1 + Levodopa (150mg)\*1 + Entacapone (200\*2\*0,33) + Amantadine (100mg)\*2 | 982 |
| 7 | Rasagiline (1mg) | 100 | 7 | Levodopa (200mg)\*1 + Entacapone (200mg)\*1 + Pramipexole (2,1mg)\*1 + Rasagiline (1mg)\*1 + Amantadine (100mg)\*1 | 676 |
| 8 | Levodopa (100mg)\*6.5 | 650 | 8 | Levodopa (100mg)\*2 + Pramipexole (2,1mg)\*1 + Rasagiline (1mg)\*1 | 510 |
| 9 | Levodopa (100mg)\*2 + Ropinirole (8mg)\*1 + Ropinirole (4 mg)\*1 | 440 | 9 | Levodopa (50mg)\*5 + Levodopa (200mg)\*5 + Entacapone (200mg)\*5 + Rasagiline (1mg) | 1680 |
| 10 | Levodopa (150mg)\*3 + Entacapone (200mg)\*3 + Rasagiline (100mg)\*1 | 748 | 10 | Rotigotine (8mg)\*1 | 240 |
| 11 | Levodopa (250mg)\*3 + Piribedil ER (50mg)\*3 | 900 | 11 | Pramipexole ER (2,1mg)\*1 + Rasagiline (1mg)\*1 | 310 |
| 12 | Levodopa (100mg)\*2 + Levodopa (200mg)\*4 + Entacapone (200mg)\*4 + Ropinirole (8mg)\*1 + Ropinirole (4mg)\*1 | 1504 | 12 | Levodopa (100mg)\*3 + Piribedil ER (50mg)\*3 | 450 |
| 13 | Levodopa (75mg)\*2 + Levodopa (50mg)\*1 + Entacapone (200mg)\*3 + Ropinirole (4mg)\*1 + Ropinirole (2mg)\*1 | 518 | 13 | Levodopa (100mg)\*1 + Levodopa (100mg)\*4 + Entacapone (200mg)\*4 + Rasagiline (1mg)\*1 | 864 |
| 14 | Levodopa (250mg)\*5 + Rasagiline (1mg)\*1 | 1350 | 14 | Levodopa (250mg)\*3 + Pramipexole (0,7mg)\*3 + Amantadine (100mg)\*3 | 1260 |
| 15 | Levodopa (200mg)\*3 | 600 | 15 | Piribedil ER (50mg)\*1 + Rasagiline (1mg)\*1 + Rotigotine (16mg)\*1 | 630 |
| 16 | Levodopa (150mg)\*3 + Entacapone (200mg)\*3 + Rasagiline (100mg)\*1 | 748 | 16 | Levodopa (100mg)\*6 + Rasagiline (1mg)\*1 | 700 |
|  |  |  | 17 | Levodopa (100mg)\*4 + Entacapone (200mg)\*2 + Ropinirole ER (8mg)\*2 + Ropinirole ER (4mg)\*1 | 932 |
|  |  |  | 18 | Levodopa CR (200mg)\*1 + Levodopa (100mg)\*3 + Levodopa (50mg)\*1 + Entacapone (200mg)\*4 + Ropinirole ER (8mg)\*1 + Rasagiline (1mg)\*1 | 1024 |

# References

Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. *Movement Disorders* 25, 2649–2653.

Schade, S., Mollenhauer, B., & Trenkwalder, C. (2020). Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. *Movement disorders clinical practice*, *7*(3), 343-345.